Did you do any comparative studies with the rest of Canada on the quality of life or the health of patients who are taking the medications? Have you evaluated the effectiveness of these medications? This is what we are being asked.
Some witnesses have come to tell us that access to new medications was difficult, because many were rejected, especially medications for rare diseases. Some would even like to see different processes for different diseases, because the sample is too small and too many products are rejected. In Quebec, the process is different. Does that have a more positive impact on the patients' quality of life?